Abivax develops medicines that alter the body's natural immune system mechanisms.
Abivax has raised $45.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in May 2026.
Abivax's investors include TCG Crossover, Samsara BioCapital, Sofinnova Partners, Great Point Partners, Deerfield.
Abivax is headquartered in Paris, France.
Abivax develops medicines that alter the body's natural immune system mechanisms.
Abivax is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Abivax — Funding & Investors." VCBacked, May 5, 2026, https://www.vcbacked.co/company/abivax. Accessed September 30, 2026.
VCBacked. (2026). Abivax — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/abivax
{{cite web |title=Abivax — Funding & Investors |url=https://www.vcbacked.co/company/abivax |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated